These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26449448)

  • 21. Microfoam sclerotherapy.
    Redondo P; Cabrera J
    Semin Cutan Med Surg; 2005 Dec; 24(4):175-83. PubMed ID: 16387261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
    Rabe E; Otto J; Schliephake D; Pannier F
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative stability of sodium tetradecyl sulphate (STD) and polidocanol foam: impact on vein damage in an in-vitro model.
    McAree B; Ikponmwosa A; Brockbank K; Abbott C; Homer-Vanniasinkam S; Gough MJ
    Eur J Vasc Endovasc Surg; 2012 Jun; 43(6):721-5. PubMed ID: 22507925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified Tessari Tourbillon technique for making foam sclerotherapy with silicone-free syringes.
    Whiteley MS; Patel SB
    Phlebology; 2015 Oct; 30(9):614-7. PubMed ID: 25288590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clarivein® mechano-chemical ablation an interim analysis of a randomized controlled trial dose-finding study.
    Lam YL; Toonder IM; Wittens CH
    Phlebology; 2016 Apr; 31(3):170-6. PubMed ID: 26249150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one-year follow-up results.
    Gonzalez-Zeh R; Armisen R; Barahona S
    J Vasc Surg; 2008 Oct; 48(4):940-6. PubMed ID: 18639418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation.
    Morrison N; Neuhardt DL; Rogers CR; McEown J; Morrison T; Johnson E; Salles-Cunha SX
    J Vasc Surg; 2008 Apr; 47(4):830-6. PubMed ID: 18242937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polidocanol foam stability in terms of its association with glycerin.
    Rial R; Hervas LS; Monux G; Galindo A; Martin A; Hernando M; Martinez I; Hernando A; Serrano FJ
    Phlebology; 2014 Jun; 29(5):304-9. PubMed ID: 23470491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in patient-reported outcomes of varicose veins following treatment with polidocanol endovenous microfoam.
    Lal BK; Mallick R; Wright D
    Phlebology; 2017 Jun; 32(5):342-354. PubMed ID: 28114848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Air contamination in the sclerosing foam for the treatment of varicose veins.
    de Franciscis S; Nobile C; Larosa E; Montemurro R; Serra R
    Phlebology; 2016 Mar; 31(2):96-100. PubMed ID: 25514923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency.
    Yamaki T; Nozaki M; Iwasaka S
    Dermatol Surg; 2004 May; 30(5):718-22; discussion 722. PubMed ID: 15099313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified Tessari method for producing more foam.
    Xu J; Wang YF; Chen AW; Wang T; Liu SH
    Springerplus; 2016; 5():129. PubMed ID: 26933628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial.
    Ukritmanoroat T
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S35-40. PubMed ID: 21717876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of stability of polidocanol foam for nonsurgical permanent contraception.
    Guo JX; Lucchesi L; Gregory KW
    Contraception; 2015 Aug; 92(2):103-7. PubMed ID: 26070858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polidocanol concentration and time affect the properties of foam used for sclerotherapy.
    VAN Deurzen B; Ceulen RP; Tellings SS; VAN DER Geld C; Nijsten T
    Dermatol Surg; 2011 Oct; 37(10):1448-55. PubMed ID: 21790848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up.
    Ouvry P; Allaert FA; Desnos P; Hamel-Desnos C
    Eur J Vasc Endovasc Surg; 2008 Sep; 36(3):366-70. PubMed ID: 18524643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The history of sclerosing foams.
    Wollmann JC
    Dermatol Surg; 2004 May; 30(5):694-703; discussion 703. PubMed ID: 15099310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins.
    Yamaki T; Nozaki M; Sakurai H; Takeuchi M; Soejima K; Kono T
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):343-8. PubMed ID: 18922712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technical feasibility and early results of radiologically guided foam sclerotherapy for treatment of varicose veins.
    Li L; Hong XY; Zeng XQ; Luo PL; Yi Q
    Dermatol Surg; 2011 Jul; 37(7):992-8. PubMed ID: 21585599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial.
    Alòs J; Carreño P; López JA; Estadella B; Serra-Prat M; Marinel-Lo J
    Eur J Vasc Endovasc Surg; 2006 Jan; 31(1):101-7. PubMed ID: 16226901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.